BamSEC and AlphaSense Join Forces
Learn More

Gyre Therapeutics Inc.

NASDAQ: GYRE    
Share price (12/24/24): $11.90    
Market cap (12/24/24): $1.113 billion
Search in Documents
Key Exhibits
External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

EX-2.1
from 8-K 4 pages Second Amendment to Business Combination Agreement
12/34/56
EX-2.3
from 10-Q 23 pages Contingent Value Rights Agreement
12/34/56
EX-2.5
from S-3 20 pages Contingent Value Rights Agreement
12/34/56
EX-2.3
from 10-Q 22 pages Contingent Value Rights Agreement
12/34/56
EX-2.3
from DEFA14A 2 pages Amendment to Contingent Value Rights Agreement
12/34/56
EX-2.3
from 8-K 2 pages Amendment to Contingent Value Rights Agreement
12/34/56
EX-2.2
from DEFA14A 6 pages Agreement and Amendment to Asset Purchase Agreement
12/34/56
EX-2.2
from 8-K 6 pages Agreement and Amendment to Asset Purchase Agreement
12/34/56
EX-2.1
from DEFA14A 7 pages Amendment to Business Combination Agreement
12/34/56
EX-2.1
from 8-K 7 pages Amendment to Business Combination Agreement
12/34/56
EX-2.2
from 8-K 92 pages Business Combination Agreement Among Catalyst Biosciences, Inc., Gni USA, Inc., Gni Group Ltd. Gni Hong Kong Limited Shanghai Genomics, Inc., Continent Pharmaceuticals Inc., and the Other Parties That Are Signatories Hereto Dated as of December 26, 2022
12/34/56
EX-2.2
from 425 92 pages Business Combination Agreement Among Catalyst Biosciences, Inc., Gni USA, Inc., Gni Group Ltd. Gni Hong Kong Limited Shanghai Genomics, Inc., Continent Pharmaceuticals Inc., and the Other Parties That Are Signatories Hereto Dated as of December 26, 2022
12/34/56
EX-2.1
from 425 59 pages Asset Purchase Agreement by and Among Catalyst Biosciences, Inc., as the Buyer, and Gni Group Ltd., and Gni Hong Kong Limited, as the Sellers Dated as of December 26, 2022 This Document Is Not Intended to Create, Nor Will It Be Deemed to Create, a Legally Binding or Enforceable Offer or Agreement, Acceptance of an Offer or Agreement of Any Type or Nature, Unless and Until Agreed to and Executed by All Parties Hereto
12/34/56
EX-2.1
from 8-K 59 pages Asset Purchase Agreement by and Among Catalyst Biosciences, Inc., as the Buyer, and Gni Group Ltd., and Gni Hong Kong Limited, as the Sellers Dated as of December 26, 2022 This Document Is Not Intended to Create, Nor Will It Be Deemed to Create, a Legally Binding or Enforceable Offer or Agreement, Acceptance of an Offer or Agreement of Any Type or Nature, Unless and Until Agreed to and Executed by All Parties Hereto
12/34/56
EX-2.1
from 8-K 117 pages Agreement and Plan of Merger Among: Targacept, Inc., a Delaware Corporation; Talos Merger Sub, Inc., a Delaware Corporation; and Catalyst Biosciences, Inc., a Delaware Corporation Dated as of March 5, 2015
12/34/56
EX-2.1
from 425 117 pages Agreement and Plan of Merger Among: Targacept, Inc., a Delaware Corporation; Talos Merger Sub, Inc., a Delaware Corporation; and Catalyst Biosciences, Inc., a Delaware Corporation Dated as of March 5, 2015
12/34/56